| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from HYFT graph: als. Moreover, in the past two years, the Company has gained increasing recognition as a rising leader in the biologic… |
| JNJ |
Johnson & Johnson |
72%
|
als. Moreover, in the past two years, the Company has gained increasing recognition as a rising leader in the biologics CRO space, with a focus on organic growth through market penetration and servic… |
| ABVERIS-INC-GENOVAC-GMBH |
ABVERIS-INC-GENOVAC-GMBH |
62%
|
ndmarkets.com, the global immunoassay market was worth U.S.$35 billion in 2023 and is anticipated to grow with a CAGR of 5.9% to U.S. $46 billion by 2028. In recent years, the number of monoclonal an… |
| ALDEVRON-LLC |
ALDEVRON-LLC |
62%
|
brief biographies of our directors and executive officers. Dr. Jennifer Bath Dr. Bath is the CEO and President of IPA. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunolo… |
| ALDEVRON-LLC-ANTIBODY-SOLUTIONS-GENSCRIPT-BIOTEC |
ALDEVRON-LLC-ANTIBODY-SOLUTIONS-GENSCRIPT-BIOTEC |
62%
|
ndmarkets.com, the global immunoassay market was worth U.S.$35 billion in 2023 and is anticipated to grow with a CAGR of 5.9% to U.S. $46 billion by 2028. In recent years, the number of monoclonal an… |
| CANADA-LTD |
CANADA-LTD |
62%
|
ancing activities: Proceeds from share issuance, net of transaction costs 12 12,228 2,360 716 Proceeds from debenture 10 4,242 — — Repayment of principal on leases 11 ( 1,577 ) ( 1,339 ) ( 1,337 ) Ne… |
| DELAWARE-TALEM-THERAPEUTICS-LLC |
DELAWARE-TALEM-THERAPEUTICS-LLC |
62%
|
business activities in Canada and a significant portion of the Company’s business activities depend on foreign operations in the Netherlands and the United States. The Company distributes and offers … |
| EXECUTIVE-OFFICERS-NAME-POSITION-WITH-IMMUNOPREC |
EXECUTIVE-OFFICERS-NAME-POSITION-WITH-IMMUNOPREC |
62%
|
Item 4.B. – Business Overview – Proprietary Protection for a listing of patents and product development in progress. D. Trend Info rmation See Item 5.A. – Operating Results – Seasonality for trend in… |
| IMMP |
Immutep Limited |
62%
|
Reciprocal relationship from IMMP graph: Reciprocal relationship from HYFT graph: Reciprocal relationship from IMMP graph: Reciprocal relationship from HYFT graph: Reciprocal relationship from IMMP g… |
| IMMUNOPRECISE-ANTIBODIES-LTD |
IMMUNOPRECISE-ANTIBODIES-LTD |
62%
|
the record keeping requirements that apply to a QEF (as defined below under the heading “ Certain Material United States Federal Income Tax Considerations ”), or that we will supply U.S. Holders with… |
| KBC-GROUP |
KBC-GROUP |
62%
|
brief biographies of our directors and executive officers. Dr. Jennifer Bath Dr. Bath is the CEO and President of IPA. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunolo… |
| LAKE-PHARMA-INC |
LAKE-PHARMA-INC |
62%
|
ndmarkets.com, the global immunoassay market was worth U.S.$35 billion in 2023 and is anticipated to grow with a CAGR of 5.9% to U.S. $46 billion by 2028. In recent years, the number of monoclonal an… |
| MA-LLC |
MA-LLC |
62%
|
ancing activities: Proceeds from share issuance, net of transaction costs 12 12,228 2,360 716 Proceeds from debenture 10 4,242 — — Repayment of principal on leases 11 ( 1,577 ) ( 1,339 ) ( 1,337 ) Ne… |
| NATURE-OF-OPERATIONS-IMMUNOPRECISE-ANTIBODIES-LT |
NATURE-OF-OPERATIONS-IMMUNOPRECISE-ANTIBODIES-LT |
62%
|
ancing activities: Proceeds from share issuance, net of transaction costs 12 12,228 2,360 716 Proceeds from debenture 10 4,242 — — Repayment of principal on leases 11 ( 1,577 ) ( 1,339 ) ( 1,337 ) Ne… |
| N-D-LTD |
N-D-LTD |
62%
|
ancing activities: Proceeds from share issuance, net of transaction costs 12 12,228 2,360 716 Proceeds from debenture 10 4,242 — — Repayment of principal on leases 11 ( 1,577 ) ( 1,339 ) ( 1,337 ) Ne… |
| ND-LTD |
ND-LTD |
62%
|
business activities in Canada and a significant portion of the Company’s business activities depend on foreign operations in the Netherlands and the United States. The Company distributes and offers … |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
the record keeping requirements that apply to a QEF (as defined below under the heading “ Certain Material United States Federal Income Tax Considerations ”), or that we will supply U.S. Holders with… |
| TALEM-THERAPEUTICS-LLC |
TALEM-THERAPEUTICS-LLC |
62%
|
business activities in Canada and a significant portion of the Company’s business activities depend on foreign operations in the Netherlands and the United States. The Company distributes and offers … |
| USA-LTD |
USA-LTD |
62%
|
ancing activities: Proceeds from share issuance, net of transaction costs 12 12,228 2,360 716 Proceeds from debenture 10 4,242 — — Repayment of principal on leases 11 ( 1,577 ) ( 1,339 ) ( 1,337 ) Ne… |
| YA-II-PN-LTD |
YA-II-PN-LTD |
62%
|
281 45 — 16,174 291 336 6,255 110 23,492 Accumulated Depreciation: Balance, April 30, 2023 157 33 50 1,752 57 388 3,913 — 6,350 Depreciation 101 4 — 1,723 56 58 849 — 2,791 Disposals ( 110 ) ( 31 ) (… |
